Targeting histone deacetylases as a new strategy for graft versus host disease prevention

New research shows that the addition of the oral anti-cancer agent vorinostat to standard therapy given before, during, and after hematopoietic stem cell transplantation may safely reduce the incidence and severity of a challenging complication called graft-versus-host disease .

http://medicalxpress.com/news/2012-12-histone-deacetylases-strategy-graft-host.html